Ikena Oncology, Inc. (IKNA) Stock Analysis & Investment Frameworks
Ikena Oncology, Inc. (IKNA) stock analysis on Invetso. Review Ikena Oncology, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Ikena Oncology, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Ikena Oncology, Inc. Key Financial Metrics
- Market Cap: $718.82M
- Revenue: $N/A
- ROE: -50.21%
- ROIC: -35.80%
- Dividend Yield: N/A
About Ikena Oncology, Inc.
Ikena Oncology, Inc. is a biopharmaceutical company specializing in precision oncology. Its primary objective is to create therapeutic agents specifically formulated for patient populations identified through biomarkers, thereby addressing significant unmet medical needs. The company's leading drug candidate is IK-930, an orally administered small molecule designed to inhibit the transcriptional enhanced associate domain (TEAD) transcription factor, a key component of the Hippo signaling pathway. Ikena is also progressing a portfolio of other investigational therapies, including: A small molecule inhibitor program targeting ERK5 within the RAS signaling pathway. IK-175, an oral compound that inhibits the aryl hydrocarbon receptor. IK-007, an orally delivered, selective antagonist of the EP4 receptor, which is being developed for the treatment of microsatellite stable colorectal cancer. Founded in 2016, the company is based in Boston, Massachusetts.